BRISTOL-MYERS SQUIBB COMPANY Proceeds from Sale of Equity Method Investments
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Proceeds from Sale of Equity Method Investments of $218.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2023-02-14
- BRISTOL-MYERS SQUIBB COMPANY proceeds from sale of equity method investments for fiscal 2022 was $218.00M, a 91.55% decline from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from sale of equity method investments for fiscal 2021 was $2.58B, a 1899.22% increase from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from sale of equity method investments for fiscal 2020 was $129.00M, a 22.75% decline from fiscal 2019.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from sale of equity method investments for fiscal 2019 was $167.00M.
| Period end | Proceeds from Sale of Equity Method Investments 12 month |
|---|---|
| 2022-12-31 | $218.00M 10-K · filed 2023-02-14 |
| 2021-12-31 | $2.58B 10-K · filed 2023-02-14 |
| 2020-12-31 | $129.00M 10-K · filed 2023-02-14 |
| 2019-12-31 | $167.00M 10-K · filed 2022-02-09 |
| 2008-12-31 | $1.01B 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |